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To the editor:
Mutational analysis of SHOC2, a novel gene for Noonan-like syndrome, in JMML
Cordeddu et al recently reported the discovery of a specific SHOC2 gene
mutation underlying a variant of the neuro-cardio-facio-cutaneous
(NCFC) syndrome family.1 The common denominator of mutations
associated with this group of disorders is their involvement in the
dysregulation of the Ras–mitogen-activated protein kinase (MAPK)
pathway.2 Mutant SHOC2 undergoes aberrant N-myristoylation that
results in constitutive membrane targeting. This in turn is thought to
sustain RAF1-stimulated MAPK activation.1
The Ras-MAPK pathway is central also to the pathophysiology
of juvenile myelomonocytic leukemia (JMML) and related myelo-
proliferative neoplasms.3 Leukemogenic perturbation of the Ras-
MAPK pathway in nonsyndromic children results from somatic
lesions of the same genes that cause NCFC syndromes when
mutated in the germ line, as exemplified by PTPN114 and KRAS.5
Moreover, some disorders of the NCFC spectrum (notably Noonan
syndrome and neurofibromatosis type 1 [NF-1]) constitute a
predisposition for the development of myeloproliferative neo-
plasms in childhood.
Together, these findings provide a strong rationale to investigate
the possible occurrence of somatic SHOC2 mutations in nonsyn-
dromic JMML. Mutations affecting Ras pathway–related genes can
be defined in approximately 80% of JMML cases (PTPN11 35%,
KRAS/NRAS 25%, CBL 10%, NF1 11%) and are, with very few
exceptions, mutually exclusive in the same patient. We performed
SHOC2 mutation analyses in a cohort of 22 JMML cases prese-
lected for the absence of mutations in PTPN11, KRAS/NRAS or
CBL and without clinical NF-1 features. All children had been
enrolled in the European Working Group of Myelodysplastic
Syndromes in Childhood (EWOG-MDS) studies 98 or 2006, and
samples had been taken after informed consent of patients’
guardians. The entire SHOC2 coding sequence was analyzed by
genomic sequencing in granulocyte DNA from bone marrow or
peripheral blood of the 22 JMML patients. However, we discovered
no pathologic sequence variations.
In conclusion, we found no evidence of leukemogenic SHOC2
involvement in JMML. Although the genetic link between NCFC
syndromes and JMML is well established for some Ras-MAPK
pathway genes such as PTPN11 and KRAS, the absence of SHOC2
mutations in JMML underscores that this phenotypic duality is not
a universal feature of all Ras-related genes. We have previously
reported a similar observation for SOS1.6 It is obvious that the
leukemogenic potential of Ras-MAPK pathway mutations differs
between individual genes.
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